Capital Investment Advisors LLC Sells 1,226 Shares of Bristol-Myers Squibb (NYSE:BMY)

Capital Investment Advisors LLC trimmed its stake in Bristol-Myers Squibb (NYSE:BMY) by 0.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 259,514 shares of the biopharmaceutical company’s stock after selling 1,226 shares during the period. Capital Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $13,427,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in BMY. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb in the 1st quarter worth approximately $27,000. ORG Wealth Partners LLC bought a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $34,000. LGT Financial Advisors LLC increased its position in Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 227 shares during the period. Redmont Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the 1st quarter worth approximately $47,000. Finally, MFA Wealth Advisors LLC bought a new position in Bristol-Myers Squibb in the 2nd quarter worth approximately $39,000. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have commented on BMY. Deutsche Bank Aktiengesellschaft dropped their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. BMO Capital Markets reaffirmed a “market perform” rating and issued a $48.00 price target on shares of Bristol-Myers Squibb in a research report on Monday, September 23rd. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. UBS Group raised their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 9th. Finally, TD Cowen boosted their price target on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $53.20.

Bristol-Myers Squibb Stock Up 0.1 %

BMY opened at $53.23 on Friday. The firm’s 50-day simple moving average is $50.36 and its 200-day simple moving average is $46.42. The company has a debt-to-equity ratio of 2.86, a quick ratio of 1.02 and a current ratio of 1.16. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $57.09. The firm has a market cap of $107.90 billion, a price-to-earnings ratio of -17.17, a PEG ratio of 13.75 and a beta of 0.46.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The business had revenue of $12.20 billion for the quarter, compared to analyst estimates of $11.54 billion. During the same quarter in the prior year, the firm earned $1.75 EPS. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. Equities research analysts anticipate that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Investors of record on Friday, October 4th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, October 4th. This represents a $2.40 annualized dividend and a yield of 4.51%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.